{"id":"NCT01450943","sponsor":"VA Office of Research and Development","briefTitle":"VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic","officialTitle":"A Comparative Efficacy Study: Treatments of Non-Healing Diabetic Foot Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10-01","primaryCompletion":"2017-12-14","completion":"2018-04-04","firstPosted":"2011-10-13","resultsPosted":"2019-09-17","lastUpdate":"2019-09-17"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Foot Ulcer"],"interventions":[{"type":"DEVICE","name":"SECONDARY dressing gauze and tape","otherNames":[]},{"type":"PROCEDURE","name":"debridement, irrigation","otherNames":[]},{"type":"DEVICE","name":"Dermagraft","otherNames":[]},{"type":"DEVICE","name":"Oasis","otherNames":[]}],"arms":[{"label":"Standard of care","type":"ACTIVE_COMPARATOR"},{"label":"Dermagraft","type":"EXPERIMENTAL"},{"label":"Oasis","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to assess the effectiveness of cellular dermal replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.","primaryOutcome":{"measure":"Wound Closure by Week 15","timeFrame":"15 weeks","effectByArm":[{"arm":"Standard of Care","deltaMin":10,"sd":null},{"arm":"Dermagraft","deltaMin":15,"sd":null},{"arm":"Oasis","deltaMin":9,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.0517"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":16},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23298410"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":28},"commonTop":["Non-study related"]}}